Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 239 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Men’s skin cancer rates increase by 50% over decade June 24, 2021 Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown October 20, 2020 Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... December 3, 2021 Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... April 24, 2019 Load more HOT NEWS What is Mindfulness? UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation The Recently Leaked Secret to Marijuana News Discovered Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC...
